Patents by Inventor Sophie Lucas

Sophie Lucas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LAGE-1 tumor associated nucleic acids
    Publication number: 20040234541
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Application
    Filed: June 25, 2004
    Publication date: November 25, 2004
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • Lage-1 tumor associated nucleic acids
    Patent number: 6794131
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: September 21, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
    Patent number: 6680191
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: January 20, 2004
    Assignee: Ludwig Institute for Cancer
    Inventors: Sophie Lucas, Thierry Boon-Falleur
  • Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
    Publication number: 20030170256
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Application
    Filed: June 4, 2002
    Publication date: September 11, 2003
    Inventors: Sophie Lucas, Charles De Smet, Thierry Boon-Falleur
  • Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
    Publication number: 20020176865
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Application
    Filed: March 1, 2002
    Publication date: November 28, 2002
    Inventors: Sophie Lucas, Thierry Boon-Falleur
  • Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
    Patent number: 6475783
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: November 5, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Sophie Lucas, Charles De Smet, Thierry Boon-Falleur
  • Leukemia associated genes
    Patent number: 6271019
    Abstract: The invention describes leukemia associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a preproTRH, tryptase-L and/or Oct-T1 gene product.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: August 7, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Nicolas Van Baren, Pierre G. Coulie, Charles DeSmet, Sophie Lucas, Thierry Boon-Falleur
  • Leukemia associated genes
    Patent number: 6130052
    Abstract: The invention describes leukemia associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a preproTRH, tryptase-L and/or Oct-T1 gene product.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: October 10, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Nicolas Van Baren, Pierre G. Coulie, Charles DeSmet, Sophie Lucas, Thierry Boon-Falleur
  • Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
    Patent number: 6027924
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the DNA sequence or vectors which comprise the DNA sequence. Various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes are also part of this invention.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: February 22, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Sophie Lucas, Charles De Smet, Thierry Boon-Falleur
  • Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
    Patent number: 5997872
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the DNA sequence or vectors which comprise the DNA sequence. Various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes are also part of this invention.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: December 7, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Sophie Lucas, Charles De Smet, Thierry Boon-Falleur
  • Methods for determining expression of NAG tumor rejection antigen precursor
    Patent number: 5958711
    Abstract: New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: September 28, 1999
    Assignee: Inserm (Institute National De La Sante Et De La Recherche Medicale
    Inventors: Yannick Guilloux, Francine Jotereau, Thierry Boon-Falleur, Sophie Lucas, Vincent Brichard
  • Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
    Patent number: 5886145
    Abstract: New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: March 23, 1999
    Assignee: INSERM (Institute National de la Sante et de la Rechereche Medicale)
    Inventors: Yannick Guilloux, Francine Jotereau, Thierry Boon-Falleur, Sophie Lucas, Vincent Brichard
  • Leukemia associated genes
    Patent number: 5879892
    Abstract: The invention describes leukemia associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a preproTRH, tryptase-L and/or Oct-T1 gene product.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: March 9, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Nicolas Van Baren, Pierre G. Coulie, Charles DeSmet, Sophie Lucas, Thierry Boon-Falleur
  • Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
    Patent number: 5821122
    Abstract: New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 13, 1998
    Assignee: Inserm (Institute Nat'l de la Sante et de la Recherche . .)
    Inventors: Yannick Guilloux, Francine Jotereau, Thierry Boon-Falleur, Sophie Lucas, Vincent Brichard
  • LL-1 tumor specific genes
    Patent number: 5811519
    Abstract: The invention describes the LL-1 tumor specific gene family, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LL-1 gene product.
    Type: Grant
    Filed: January 27, 1997
    Date of Patent: September 22, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur